|Event Time:||Friday April 27, 2018 1:00 pm to 3:00 pm|
|Description:||A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.|
|2:35 PM - 3:00 PM||Discussion||Faculty|
|1:00 PM||001||A Neurology Practice Based Research Network for Quality Improvement and Practice Based Research Using the EMR||
Dr. Simon has nothing to disclose.
|1:12 PM||002||Burnout Prevention Measures - Do They Meet the Needs of Women Neurologists?||
Dr. Moore has nothing to disclose.
|1:24 PM||003||Validation of a Porcine Model for White Matter Developmental Trajectories||
Dr. Cacic has nothing to disclose.
|1:36 PM||004||Pineal cysts: a long term follow-up||
Sarah Wright, PhD, FRACP
Dr. Wright has nothing to disclose.
|1:48 PM||005||LGI1 Limbic Encephalitis after Interleukin-2 Therapy||
Dr. Beaver has nothing to disclose.
|2:00 PM||006||Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis: Crest-2||
James Meschia, MD, FAAN
Dr. Meschia has nothing to disclose.
|2:12 PM||007||Baseline cognitive function among participants in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (Crest-2)||
Ronald Lazar, PhD, FAHA, FAAN
Dr. Lazar has nothing to disclose.
|2:24 PM||008||Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine||
Linda A. Wietecha
Dr. Wietecha has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Wietecha has received compensation for serving on the Board of Directors of Eli Lilly and Company.